Dr. Reddy launches Guaifenesin and Pseudoephedrine
Dr. Reddy's Laboratories has launched an over-the-counter (OTC) store-brand equivalent of Mucinex D Extended-Release Tablets in two strengths-Guaifenesin 600 mg and Pseudoephedrine HCI 60 mg, and Guaifenesin 1200 mg and Pseudoephedrine HCI 120 mg in the United States market, as approved by the US Food and Drug Administration (USFDA).
Guaifenesin and Pseudoephedrine HCI is used to help loosen phlegm (mucus) and thin bronchial secretions to rid the bronchial passageways of bothersome mucus and make coughs more productive; temporarily relieve nasal congestion due to common cold, hay fever, and upper respiratory allergies; temporarily restore freer breathing through the nose; promote nasal and/or sinus drainage; and temporarily relieve sinus congestion and pressure.
According to IRI, the Mucinex D brand and store brands had combined US sales of around US$71 million MAT for the most recent twelve months ending in May 2019.
Dr. Reddy's Laboratories is a multinational pharmaceutical company based in Hyderabad, Telangana in India. It manufactures and markets a wide range of pharmaceuticals in India and overseas.
The shares of the company closed at Rs. 2,593 per share, 0.11 per cent lower than its previous close of Rs. 2,595.75, while its intraday high was Rs. 2,630 and intraday low was Rs. 2,572.90.